Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders

Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders

Show other versions (1)

Objective: The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine,...

Full description

Bibliographic Details
Main Authors: Fatemeh Salari, Mohammad Shahjahani, Seyed Ahmad Hosseini, Ali Dehghani Fard, Kaveh Jaseb
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2013-07-01
Series:International Journal of Hematology-Oncology and Stem Cell Research
Subjects:
Fetal Hemoglobin
β-hemoglobinopathies
Histone Deacetylase
Online Access:http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/405/430

Internet

http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/405/430

Similar Items